Related Experiment Video
Updated: Jul 8, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Somatostatin with 99mTc and biodistribution studies in rats
Cigdem Acar1, Serap Teksöz, Perihan Unak
1Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Bornova Izmir, Turkey.
Cancer Biotherapy & Radiopharmaceuticals
|December 27, 2007
Summary
This study compared two chelating agents for labeling somatostatin (SST) with technetium-99m. The (99m)Tc-D-PA-SST complex showed longer organ uptake and slower clearance, suggesting potential for improved diagnostic imaging.
Area of Science:
- Endocrinology
- Radiopharmaceutical Chemistry
- Nuclear Medicine
Background:
- Somatostatin (SST) is a peptide hormone regulating endocrine functions.
- SST derivatives are used in diagnosing growth hormone disorders and certain cancers.
- SST also impacts gastric acid, gallbladder, and pancreatic secretions.
Purpose of the Study:
- To investigate the impact of different bifunctional chelating agents on the biologic half-life of somatostatin (SST).
- To compare the radiopharmaceutical potential of three (99m)Tc-labeled complexes involving SST.
Main Methods:
- Labeling SST with (99m)Tc using D-penicillamine (D-PA) and diethylene triaminepentaacetic acid (DTPA).
- Evaluating three complexes: (99m)Tc-D-PA, (99m)Tc-D-PA-SST, and (99m)Tc-DTPA-SST.
- Assessing complex stability via radiochromatographic methods and performing biodistribution studies in rats.
Main Results:
- All radiolabeled complexes demonstrated stability for up to 5 hours.
- (99m)Tc-D-PA-SST exhibited prolonged organ uptake.
- The clearance of (99m)Tc-D-PA-SST was slower compared to (99m)Tc-DTPA-SST.
Conclusions:
- The choice of chelating agent significantly influences the biodistribution of (99m)Tc-labeled SST.
- (99m)Tc-D-PA-SST shows potential for enhanced diagnostic applications due to its prolonged retention.
- Further research may optimize SST-based radiopharmaceuticals for improved therapeutic and diagnostic outcomes.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...